Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies

Ashley L Cole; Hanna K Sanoff; Stacie B Dusetzina

doi:10.1001/jamainternmed.2017.2788

Possible Insufficiency of Generic Price Competition to Contain Prices for Orally Administered Anticancer Therapies

JAMA Intern Med. 2017 Nov 1;177(11):1679-1680. doi: 10.1001/jamainternmed.2017.2788.

Authors

Ashley L Cole¹, Hanna K Sanoff^{2

3}, Stacie B Dusetzina^{1

3

4

5}

Affiliations

¹ Division of Pharmaceutical Outcomes and Policy, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill.
² Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.
³ School of Medicine, University of North Carolina, Chapel Hill.
⁴ Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill.
⁵ Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill.

Abstract

This study traces the use of the anticancer drug capecitabine through its loss of patent protection to evaluate the effect of generic pricing on the cost of oral anticancer drugs.

MeSH terms

Adolescent
Adult
Antineoplastic Agents / economics*
Capecitabine / economics*
Databases, Factual
Drug Costs / statistics & numerical data*
Drugs, Generic / economics*
Economic Competition / statistics & numerical data
Humans
Middle Aged
Young Adult

Substances

Antineoplastic Agents
Drugs, Generic
Capecitabine

Grants and funding

P30 CA016086/CA/NCI NIH HHS/United States